The drug development pipeline for glioblastoma: a cross sectional assessment of the FDA Orphan Drug Product designation database
Background Glioblastoma (GBM) is the most common malignant brain tumour among adult patients and represents an almost universally fatal disease. Novel therapies for GBM are being developed under the orphan drug legislation and the knowledge on the molecular makeup of this disease has been increasing...
Gespeichert in:
| Hauptverfasser: | , , |
|---|---|
| Dokumenttyp: | Article (Journal) |
| Sprache: | Englisch |
| Veröffentlicht: |
July 7, 2021
|
| In: |
PLOS ONE
Year: 2021, Jahrgang: 16, Heft: 7, Pages: 1-14 |
| ISSN: | 1932-6203 |
| DOI: | 10.1371/journal.pone.0252924 |
| Online-Zugang: | Verlag, lizenzpflichtig, Volltext: https://doi.org/10.1371/journal.pone.0252924 Verlag, lizenzpflichtig, Volltext: https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0252924 
|
| Verfasserangaben: | Pascal Johann, Dominic Lenz, Markus Ries |
Search Result 1
“The drug development pipeline for glioblastoma: a cross sectional assessment of the FDA Orphan Drug Product designation database”
Article (Journal)
Kapitel/Artikel
Online Resource